Property | Value |
?:abstract
|
-
Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
|
?:creator
|
|
?:doi
|
-
10.1186/s12931-020-01439-4
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/033f5ab05b22f2e945306b287550da393500b585.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7351640.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19
|
?:type
|
|
?:year
|
|